Short Interest in Nyxoah SA (NASDAQ:NYXH) Drops By 63.9%

Posted by Francis Steltz on Jul 15th, 2026

Nyxoah SA (NASDAQ:NYXH – Get Free Report) saw a large drop in short interest in June. As of June 30th, there was short interest totaling 298,468 shares, a drop of 63.9% from the June 15th total of 826,117 shares. Currently, 0.9% of the company’s stock are sold short. Based on an average trading volume of 309,898 shares, the short-interest ratio is presently 1.0 days.

Analyst Upgrades and Downgrades

NYXH has been the topic of a number of recent analyst reports. Robert W. Baird set a $2.85 target price on shares of Nyxoah in a research note on Thursday, July 9th. Cantor Fitzgerald reissued an “overweight” rating and issued a $11.00 price objective on shares of Nyxoah in a report on Monday, March 23rd. Weiss Ratings cut Nyxoah from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, May 22nd. Stifel Nicolaus reduced their target price on Nyxoah from $5.00 to $3.00 and set a “hold” rating on the stock in a report on Wednesday, June 17th. Finally, Piper Sandler reiterated an “overweight” rating and issued a $7.00 target price (down from $9.00) on shares of Nyxoah in a research report on Wednesday, May 13th. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Nyxoah currently has a consensus rating of “Hold” and a consensus target price of $5.96.

Read Our Latest Report on NYXH

Nyxoah Stock Performance

Shares of NASDAQ:NYXH traded up $0.03 on Wednesday, reaching $1.61. 101,045 shares of the company’s stock were exchanged, compared to its average volume of 165,902. The firm has a market capitalization of $62.40 million, a price-to-earnings ratio of -0.65 and a beta of 1.61. Nyxoah has a fifty-two week low of $1.26 and a fifty-two week high of $8.59. The business’s 50-day moving average is $2.20 and its two-hundred day moving average is $3.36. The company has a quick ratio of 0.88, a current ratio of 0.99 and a debt-to-equity ratio of 0.53.

Nyxoah (NASDAQ:NYXH – Get Free Report) last posted its quarterly earnings results on Tuesday, May 12th. The company reported ($0.43) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.11. Nyxoah had a negative net margin of 543.21% and a negative return on equity of 163.73%. The company had revenue of $7.38 million for the quarter, compared to the consensus estimate of $7.05 million. As a group, equities research analysts forecast that Nyxoah will post -1.67 EPS for the current year.

Hedge Funds Weigh In On Nyxoah

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Raymond James Financial Inc. acquired a new stake in shares of Nyxoah during the 2nd quarter worth approximately $70,000. Bank of America Corp DE boosted its position in Nyxoah by 72.4% during the 2nd quarter. Bank of America Corp DE now owns 7,866 shares of the company’s stock valued at $59,000 after purchasing an additional 3,303 shares during the period. Shay Capital LLC acquired a new position in Nyxoah during the 2nd quarter valued at approximately $374,000. Citadel Advisors LLC bought a new position in Nyxoah during the 3rd quarter worth $98,000. Finally, Deutsche Bank AG grew its stake in Nyxoah by 40.0% during the 4th quarter. Deutsche Bank AG now owns 35,000 shares of the company’s stock worth $161,000 after buying an additional 10,000 shares during the last quarter.

Nyxoah Company Profile

(Get Free Report)

Nyxoah SA, headquartered in Mont-Saint-Guibert, Belgium, is a medical technology company focused on neuromodulation therapies for sleep‐disordered breathing. Established in 2018, the company’s primary offering is the Genio® system, a minimally invasive bilateral hypoglossal nerve stimulator designed to treat moderate to severe obstructive sleep apnea (OSA). By electrically stimulating the genioglossus muscle, the device helps maintain airway patency during sleep, reducing apnea events and improving overall sleep quality.

The Genio system comprises a small, implantable stimulator positioned submentally and an external activation unit worn by the patient.